Team & Science
The people, and what they have published.
At preclinical stage, the team and the published work are the evidence a partner has. Both are named here.
Founders
Dr. Élise Corvin
Co-founder and CEO
Immunologist. Previously led a synovial-biology group in academia before founding Corvin around the single-driver approach.
Dr. Amir Nasser
Co-founder and Chief Scientific Officer
Medicinal chemist. Built the CVT-101 series from the founding target and leads the chemistry across all three programs.
Scientific advisory board
Dr. Priya Raman
Rheumatology, clinical translation
Dr. Thomas Beaulieu
Kinase pharmacology
Dr. Wei Zhang
Preclinical safety and toxicology
Selected publications
Downstream kinase signalling in synovial fibroblasts: a targetable node.
Corvin É., Beaulieu T., et al. Journal of Autoimmune Research, 2025.
Selectivity profiling of an oral kinase inhibitor series for autoimmune indications.
Nasser A., Zhang W., et al. Medicinal Chemistry Letters, 2024.
Single-driver targeting versus broad immunosuppression: a preclinical framework.
Raman P., Corvin É., et al. Frontiers in Immunology, 2024.